Indefinite Delivery Contract SPE2DR25D9238

The key details of this federal Indefinite Delivery Contract (IDC) are as follows:

The IDC was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The contract is valued at $499,999,999 and runs through November 2026, allowing the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. This positions DMS Pharmaceutical Group as a critical supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense (DoD) healthcare sites.

The IDC was originally solicited under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which aims to establish multiple regional prime vendor contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, United States Coast Guard, and US Naval Fleet. The $30.3 billion acquisition will be awarded on a lowest price technically acceptable basis, with the intent to have at least three different contractors across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet regions to ensure supply chain resiliency.